|
|
|
| Effects of different dose of Clopidogrel combined with Aspirin on GMP-140, platelet aggregation rate and safety in patients with unstable angina pectoris |
| ZHOU Xiangping |
| Dongfeng Community Health Service Center of Chaoyang District, Beijing 100016, China |
|
|
|
Abstract Objective To explore the clinical efficacy and safety of different dose of Clopidogrel combined with Aspirin in the treatment of unstable angina pectoris (UAP). Methods From May 2016 to May 2017, 180 patients with UAP treated in Dongfeng Community Health Service Center of Chaoyang District, Beijing, and they were divided into A, B, C group, with 60 cases in each group. On the basis of Aspirin treatment, group A, B, C were treated with Clopidogrel 25, 50 and 75 mg/d orderly. The three groups were treated for 90 d. Efficacy and adverse reactions of the patients were retrospectively analyzed. Results After treatment, the level of GMP-140 in group B and C was lower than that in group A (P ＜ 0.05), the rate of platelet aggregation induced by ADP was also lower than that in group A (P ＜ 0.05), but there was no significant difference between group B and C (P ＞ 0.05). The total effective rate of treatment in group B and C were higher than that in group A (P ＜ 0.05), and the frequency of UAP in group B and C was less than that in group A, the duration of UAP was shorter in group B and C (P ＜ 0.05), while there was no significant difference between group B and C (P ＞ 0.05). There was no severe adverse reactions in the three groups, and there was no significant difference in the incidence of mild adverse reactions among the three groups (P ＞ 0.05). Adverse cardiovascular events rate in group B and C was less than that in group A (P ＜ 0.05). Conclusion Compared with other doses, 50, 75 mg/d Clopidogrel combined with Aspirin regimen in the treatment of UAP can get accurate effect, and it shows good safety.
|
|
|
|
|
|
[1] 席兰艳，刘芳群，毛艳梅，等.不稳定型心绞痛合并高血压患者的药学监护模式探讨[J].中南药学，2017，15（4）：517-518.
[2] 许先继，林艳足.阿托伐他汀联合氯吡格雷对不稳定型心绞痛患者血清高敏C反应蛋白及预后的影响[J].广东医学，2014，35（11）：1766-1767.
[3] 李园，王连心，谢雁鸣.注射用丹参多酚酸盐联合阿司匹林治疗稳定型心绞痛机制的生物分子网络研究[J].中国中药杂志，2016，41（24）：4521-4522.
[4] 中华医学会心血管病分会.不稳定型心绞痛诊断和治疗建议[J].中华心血管病杂志，2000，28（6）：409-410.
[5] 彭冉.通心络联合氯吡格雷治疗冠心病心绞痛疗效与安全性的Meta分析[J].中国实验方剂学杂志，2016，22（9）：208-209.
[6] 张成杰，王海燕.丹红注射液联合氯吡格雷治疗不稳定型心绞痛[J].中国实验方剂学杂志，2015，21（20）：171-172.
[7] 林玲，何五建，陆士奇，等.辛伐他汀片联合硫酸氢氯吡格雷片治疗不稳定型心绞痛的临床研究[J].中国临床药理学杂志，2017，33（22）：2222-2223.
[8] 李云，吕云波，宋银宏.阿司匹林对不稳定型心绞痛患者血浆中5种miRNA水平的影响[J].重庆医学，2017，46（2）：178-179.
[9] 夏惠丽，王怀生，刘华.氯吡格雷联合通心络胶囊治疗老年不稳定型心绞痛的疗效[J].中国老年学杂志，2015，35（19）：5471-5472.
[10] 王雪娜，蔡林，王小飞.替格瑞洛、氯吡格雷治疗的老年不稳定心绞痛患者重大心血管不良事件及血清炎症因子水平对比观察[J].山东医药，2016，56（47）：51-52.
[11] 陈慧敏，许逸飞.曲美他嗪联合阿托伐他汀钙治疗冠心病心绞痛伴血脂异常的临床研究[J].中国临床药理学杂志，2016，32（11）：966-967.
[12] 闫颜，安俊凤，丁希正.氯吡格雷、替格瑞洛对老年不稳定型心绞痛患者炎症反应的影响[J].中国老年学杂志，2017，37（21）：5313-5314.
[13] 李小龙，陆岩，张琪.氯吡格雷联合拜阿司匹林治疗稳定型心绞痛效果观察[J].山东医药，2017，57（42）：64-65.
[14] 王赛.氯吡格雷联合阿司匹林对老年冠心病不稳定心绞痛患者血清炎性因子及心功能的影响[J].中国老年学杂志，2018，38（3）：529-530.
[15] 何振艳，郭思岐.氯吡格雷应用于冠心病治疗的临床观察[J].中国地方病防治杂志，2017，32（1）：53-54.
[16] 周杰，张志清，张淑敏.丹参多酚酸盐联合阿司匹林治疗冠心病不稳定型心绞痛的疗效及对血流动力学、血小板活性的影响[J].贵州医药，2018，42（5）：565-566.
[17] 张泽，白瑞娜，张立，等.针刺联合西药治疗冠心病心绞痛的系统评价[J].中国针灸，2015，35（4）：407-411.
[18] 万德立.硫酸氢氯吡格雷与阿司匹林联合治疗稳定型心绞痛的效果分析[J].中国当代医药，2018，25（3）：108-110.
[19] 喻俊颜.高维持量氯吡格雷联合阿司匹林治疗不稳定型心绞痛临床研究[J].中国药业，2018，27（9）：74-75.
[20] 张涛，黄家树，沈涛，等.冠心病心绞痛患者应用血府逐瘀汤联合消心痛+阿司匹林疗效观察[J].中药药理与临床，2018，34（2）：107-108.
[21] 马迪辉.阿司匹林肠溶片联合氯吡格雷治疗冠心病心绞痛的临床效果[J].中国当代医药，2018，25（8）：149-150. |
|
|
|
